



## Omega Therapeutics to Participate in Two Upcoming Investor Conferences

June 1, 2023

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in two upcoming investor conferences.

### **Jefferies Healthcare Conference**

Fireside Chat

Date: Thursday, June 8, 2023

Time: 8:30 a.m. ET

### **Goldman Sachs 44<sup>th</sup> Annual Global Healthcare Conference**

Fireside Chat

Date: Wednesday, June 14, 2023

Time: 2:40 p.m. PT / 5:40 p.m. ET

Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at [www.omegatherapeutics.com](http://www.omegatherapeutics.com). Archived replays will be available on the same website for approximately 90 days.

### **About Omega Therapeutics**

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega's approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit [omegatherapeutics.com](http://omegatherapeutics.com), or follow us on [Twitter](#) and [LinkedIn](#).

Contact: Eva Stroynowski 617.949.4370 [estroynowski@omegatx.com](mailto:estroynowski@omegatx.com)